Hytro Secures US Patent For Groundbreaking Wearable Blood Flow Restriction Technology

July 31, 2025

UK / USA (July 31, 2025) /ENDURANCE SPORTSWIRE/ – Hytro, the UK-based pioneer of wearable Blood Flow Restriction (BFR) technology, is proud to announce it has been officially granted a United States patent for its innovative BFR sportswear. The new patent, US Patent No. 12,317,940, protects Hytro’s unique design and integrated BFR mechanism through to 2040 — marking a major milestone in the company’s mission to redefine recovery and performance training for athletes globally.

This achievement makes Hytro the first and only wearable BFR product of its kind to hold patent protection in the United States, reinforcing the brand’s position as a category-defining leader in sports performance technology.

Founded and headquartered in the UK, Hytro has grown steadily across the globe, earning the trust of more than 250 elite teams worldwide, including organisations in the Premier League, Premiership Rugby, NFL, NBA, Formula 1, cycling, and individual athletes across boxing, athletics and tennis. From Manchester City Women’s FC to England Rugby and Soudal Quick-Step Cycling, Hytro’s patented BFR wearables have become an essential tool for teams pushing the boundaries of modern training and recovery.

While Hytro has already begun expanding into the US — working with leading NFL and MLB teams, players and performance coaches — securing the US patent lays the foundation for a significant acceleration of the brand’s growth and presence in the American sports market.

The patent protects Hytro’s breakthrough method of safely embedding adjustable Blood Flow Restriction directly into high-performance apparel — eliminating the need for bulky straps or complex pneumatic systems that typically require expert supervision. This makes BFR more practical and accessible for everyday athletes and coaches looking to safely gain an edge in recovery, strength and performance. Anywhere, anytime.

Dr. Warren Bradley, Founder and Head of Elite Performance at Hytro said: “This is a deeply personal milestone for me. Back in 2018, I filed the original patent for Hytro, pouring all my life’s savings and all my belief into an idea I knew had the power to change how athletes train and recover. Now, 7 years later, to hold the granted US patent and welcome investment from world-class athletes who share that belief is incredible validation. We’ve gone from a sketch on paper to a globally recognised product trusted by elite teams and now protected in the biggest market in the world. It’s been a long road, and this moment marks a major turning point.”

Raj Thiruchelvarajah, CEO and Co-Founder of Hytro, commented: “This US patent is a huge moment for Hytro. It validates the unique technology we’ve built from day one and protects the innovation that sets us apart in the market. We’ve grown rapidly from our UK roots, earning the trust of top teams across Europe — and now this gives us real momentum to expand further into the US. We’re committed to bringing the benefits of BFR to more athletes than ever before, and this milestone moves us one big step closer to that goal.”

The new patent supports Hytro’s ongoing research and development ambitions as it expands its product range and deepens collaborations with teams, universities and research partners in the US and around the world.

– ENDS –

About Hytro:

Hytro is a human performance brand pioneering wearable blood flow restriction (BFR), used by over 250 elite sports teams, from the NFL to Formula 1, and even by NASA.

Extensively tested by experts, Hytro is ideal for active or passive work, allowing athletes and coaches to Prepare, Train and Recover to the highest standards . Built on extensive scientific research, Hytro’s wearable BFR is made from high-quality fabrics chosen for comfort, performance and longevity. It features a unique in-built strap, carefully designed and positioned to deploy within seconds and ensure a safe and effective workout, making BFR adaptations more accessible than ever before.

Contact:

Matt.williams@keepcomms.com
07818364184